Results 221 to 230 of about 191,162 (262)
Some of the next articles are maybe not open access.
â–¼Denosumab for postmenopausal osteoporosis?
Drug and Therapeutics Bulletin, 2012Osteoporosis is the most common clinical disorder of bone metabolism, and is characterised by low bone mass and deterioration of the microarchitecture of bone tissue that results in increased bone fragility and susceptibility to bone fracture.1 In the UK, it is estimated that osteoporosis affects over 3 million people and leads to 230,000 fractures per
openaire +2 more sources
Treatment of Postmenopausal Osteoporosis
JAMA, 2001POSTMENOPAUSAL OSTEOPOROSIS IS a common and serious clinical problem. As both individuals and society have come to recognize the importance of preventing and treating osteoporosis, several new medications have been developed that have been shown to reduce fracture rates in women with osteoporosis.
D, Altkorn, T, Vokes
openaire +2 more sources
Postmenopausal osteoporosis and alendronate
Maturitas, 2004Osteoporosis is a systemic metabolic disorder associated with a decreased bone mass and resistance. Bisphosphonates suppress bone resorption and bone turnover by a mechanism that depends on their structure. They are characterized by low gastrointestinal absorption. In postmenopausal women, alendronate (ALN) reduces bone resorption markers and increases
openaire +2 more sources
CALCITONIN AND POSTMENOPAUSAL OSTEOPOROSIS
Clinical Endocrinology, 1984SUMMARYFasting serum calcitonin levels were measured in 54 postmenopausal women who had for 10 years been taking part in a double blind trial to assess the effect of the synthetic oestrogen, mestranol, on postmenopausal bone loss. There were no differences in calcitonin levels between mestranol treated and placebo groups, Fifteen of the women were ...
J, Leggate +5 more
openaire +2 more sources
Postmenopausal osteoporosis management
Current Opinion in Obstetrics and Gynecology, 2000Osteoporosis is perhaps the widest-ranging social, physical, and economic impact of estrogen deficiency. Postmenopausal bone loss is the major determinant of osteoporosis. Osteoporotic risk can be determined by measuring bone mineral density using dual X-ray absorptiometry.
M, Gambacciani, M, Ciaponi
openaire +2 more sources
Treatment of Postmenopausal Osteoporosis
Drugs, 1979Bone loss can be prevented by standard oestrogen replacement therapy and delayed by the administration of calcium supplements. The most suitable patients to treat are those with a raised urinary hydroxyproline or other evidence of rapid bone loss. Patients aged below 65 years with established osteoporosis, and in whom oestrogens are not contraindicated,
openaire +2 more sources
ESTROGENS AND POSTMENOPAUSAL OSTEOPOROSIS
Clinical Obstetrics and Gynecology, 1976A model for the development of osteoporosis is presented and the tre atment of the condition with estrogens is discussed. It appears that an age-related reduction in circulating estrogens accompanies menopausal bone loss. However this loss is more directly attributable to the lack of parathyroid hormone (PTH) while estrogens play a role in the bony ...
openaire +2 more sources
Treatment of postmenopausal osteoporosis
The Lancet, 2002The aim of treatment of postmenopausal osteoporosis is to reduce the frequency of vertebral and non-vertebral fractures (especially at the hip), which are responsible for morbidity associated with the disease. Results of large placebo controlled trials have shown that alendronate, raloxifene, risedronate, the 1-34 fragment of parathyroid hormone, and ...
openaire +2 more sources
Calcitriol for Postmenopausal Osteoporosis
Annals of Internal Medicine, 1990Excerpt To the Editor:Gallagher and Riggs (1) recently criticized the report by Ott and Chesnut (2) on calcitriol treatment in postmenopausal osteoporosis.
openaire +2 more sources